News

TRANSLATIONAL AND OPERATIONAL FIELD RESEARCH ON LYMPHATIC FILARIASIS AND ONCHOCERCIASIS Our group at Washington University School of Medicine in St. Louis has funding from the Bill & Melinda Gates Foundation to conduct cutting-edge research to support elimination programs for lymphatic filariasis and onchocerciasis. We are seeking postdoctoral fellows to (1) participate in applied field research […]

DOLF Researcher Dr. Christine Dubray, a medical epidemiologist at the Centers for Disease Control and Prevention in Atlanta, was the keynote speaker for the Washington University Medical School’s 21st Global Health & Medicine Symposium held on April 17. The title of her talk was, “A global health career on the front lines, and what I […]

DOLF investigators Christopher King and James Kazura from Case Western Reserve University in Cleveland with colleagues at the Papua New Guinea Institute for Medical Research and at Washington University in St. Louis have just published important results from a randomized clinical trial. This trial tested the safety and efficacy of a new triple drug treatment […]

Identifying solutions for enrollment, regulatory requirements, drug procurement, and improved collaboration for an international clinical trial in Hohoe Ghana By Rachel Bick and Philip BudgeOctober 5, 2018 The DOLF Project recently sent two team members, Philip Budge and Rachel Bick, to visit the Nick Opoku and the DOLF Onchocerciasis research team in Hohoe, Ghana. Our […]

The DOLF project, a collaboration of partners from Africa, Asia, the U.S. and Europe, has secured a new grant of 2.1 Million dollars from the Bill and Melinda Gates Foundation. This grant will fund a clinical trial of a new treatment for onchocerciasis, a disease caused by parasitic worms that is also known as River […]

2018 Summer Research Program Reflections  – Complexities Behind Lymphatic Filariasis July 12,2018 The blog is following the student participants in this year’s Institute for Public Health Summer Research  Program  (https://publichealth. wustl.edu/resources/summer-research­ program/). Each student will be providing their own reflections from a Summer Research Program Seminar Series (https://publichealth. wustl.edu/series/summer-research­ program-seminars/ ) event. Some students will […]

At the 2018 GAELF Meeting, Dr. Gary Weil shared perspectives on how the new treatment combination (IDA) could accelerate elimination of LF.

The DOLF project is pleased to announce that Rachel Bick has joined our team as Global Health Research Project Manager Rachel brings international experience in global health and a strong academic background to this role. She holds a Bachelor of Science in Human Factors Psychology degree from the University of Utah and a Master of Public Health […]

Uniting to Combat Neglected Tropical Diseases (NTDs) released their fifth progress report on the London Declaration on NTDs. The report describes the progress made toward achieving the goals set out by the London Declaration toward the control, elimination, and eradication of 10 NTDs. DOLF research on a more effective triple drug combination for lymphatic filariasis […]

Today Merck announced an expansion of the Mectizan Donation Program (MDP) to reach up to an additional 100 million people per year through 2025 to support the expansion of triple-drug therapy as part of the global effort to eliminate lymphatic filariasis (LF). DOLF research showed that adding ivermectin to diethylcarbamazine and albendazole can accelerate the […]

Earlier today WHO published new guidelines for alternative MDA regimens for LF in the Weekly Epidemiological Record. The new guidelines recommend: • Triple drug therapy (IDA) for use in countries using diethylcarbamazine + albendazole (DA) in special settings• Annual ivermectin + albendazole (IA) rather than biannual IA in countries endemic for LF and onchocerciasis, except […]